[1]陈红霞,陈　霞,丁雪松,等.Ⅰ型子宫腺肌病患者放置左炔诺孕酮宫内节育系统前应用不同剂量米非司酮预处理疗效比较[J].新乡医学院学报,2021,38(12):1160-1165.[doi:10.7683/xxyxyxb.2021.12.011]
　CHEN Hongxia,CHEN Xia,DING Xuesong,et al.Comparison of curative effect of different doses of mifepristone in pretreatment of type Ⅰ adenomyosis patients before placement of levonorgestrel-releasing intrauterine system[J].Journal of Xinxiang Medical University,2021,38(12):1160-1165.[doi:10.7683/xxyxyxb.2021.12.011]
点击复制

Ⅰ型子宫腺肌病患者放置左炔诺孕酮宫内节育系统前应用不同剂量米非司酮预处理疗效比较
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年12
页码:
1160-1165
栏目:
临床研究
出版日期:
2021-12-05

文章信息/Info

Title:
Comparison of curative effect of different doses of mifepristone in pretreatment of type Ⅰ adenomyosis patients before placement of levonorgestrel-releasing intrauterine system
作者:
陈红霞; 陈　霞; 丁雪松; 刘梦竹; 杨静秀
(徐州医科大学附属连云港东方医院妇产科，江苏　连云港　222042)
Author(s):
CHEN Hongxia; CHEN Xia; DING Xuesong; LIU Mengzhu; YANG Jingxiu
（Department of Obstetrics and Gynecology,Lianyungang Municipal Oriental Hospital Affiliated to Xuzhou Medical University,Lianyungang 222042,Jiangsu Province,China）
关键词:
米非司酮; 子宫腺肌病; 左炔诺孕酮宫内缓释系统; 预处理
Keywords:
mifepristone; adenomyosis; levonorgestrel-releasing intrauterine system; pretreatment
分类号:
R711.71
DOI:
10.7683/xxyxyxb.2021.12.011
文献标志码:
A
摘要:
目的　探讨Ⅰ型子宫腺肌病（AM）患者放置左炔诺孕酮宫内节育系统前应用不同剂量米非司酮预处理的疗效及不良反应。方法　选择2017年1月至2019 年5月徐州医科大学附属连云港东方医院收治的子宫明显增大且不愿接受手术治疗的Ⅰ型AM患者150例为研究对象，按照数字表法将患者随机分为A组、B组和C组，每组50例。3组患者均于月经周期第1～3天开始口服米非司酮进行预处理，每晚睡前1次。A组、B组和C组患者服用米非司酮的剂量分别为6.25、12.50、25.00 mg。直至宫腔深度≤8 cm 时放置左炔诺孕酮宫内节育系统。分别于预处理前及预处理3 个月后检测3组患者的宫腔深度、子宫体积、子宫内膜厚度、月经量及痛经疼痛程度，采用酶联免疫吸附法检测3组患者血清中雌二醇、孕酮、促卵泡生成素、糖类抗原125（CA125）水平；使用血细胞分析仪检测3组患者血红蛋白水平。记录药物预处理时间及药物不良反应；记录患者置入左炔诺孕酮宫内节育系统后6 个月内左炔诺孕酮宫内节育系统相关不良反应发生情况。结果　预处理前3组患者的宫腔深度、子宫体积、子宫内膜厚度、月经失血图(PBAC)评分及痛经视觉模拟评分法(VAS)评分比较差异均无统计学意义（P＞0.05）。预处理3个月后3组患者的宫腔深度、子宫体积、子宫内膜厚度、PBAC评分及痛经VAS评分低于预处理前（P＜0.05）。预处理3个月后，B组和C组患者的宫腔深度、子宫体积、子宫内膜厚度、PBAC评分及痛经VAS评分均低于A组（P＜0.05）；B组与C组各指标比较差异均无统计学意义（P＞0.05）。3组患者预处理前血清中雌二醇、孕酮、促卵泡生成素、CA125及血红蛋白水平比较差异均无统计学意义（P＞0.05）。3组患者预处理3个月后雌二醇、孕酮、促卵泡生成素、CA125水平低于预处理前，血红蛋白水平高于预处理前（P＜0.05）。预处理3个月后，B组和C组患者的雌二醇、孕酮、促卵泡生成素及CA125水平低于A组，血红蛋白高于A组（P＜0.05）；C组患者的雌二醇、孕酮、促卵泡生成素及CA125水平低于B组，血红蛋白高于B组（P＜0.05）。A组患者米非司酮预处理时间长于B组和C组（P＜0.05）；B组与C组患者米非司酮预处理时间比较差异无统计学意义（P>0.05）。A组、B组、C组患者药物不良反应发生率分别为4.0%（2/50）、18.0%(9/50)、42.0%(21/50)，A组患者药物不良反应发生率低于B组（χ2=5.005，P＜0.05）；B组患者药物不良反应发生率低于C组（χ2=6.857，P＜0.05）。A组、B组、C组患者左炔诺孕酮宫内节育系统相关不良反应发生率分别为34.0%（17/50）、12.0%（6/50）、8.0%（4/50），B组和C组患者左炔诺孕酮宫内节育系统相关不良反应发生率低于A组（χ2=6.832、10.187，P＜0.05）；B组与C组患者左炔诺孕酮宫内节育系统相关不良反应发生率比较差异无统计学意义（χ2=0.444，P>0.05）。结论　米非司酮每日12.5 mg的剂量用于Ⅰ型AM患者放置左炔诺孕酮宫内缓释系统前预处理临床疗效较好，不良反应少，值得临床推荐。
Abstract:
Objective　To investigate the efficacy and side effects of different doses of mifepristone in pretreatment of type Ⅰ adenomyosis (AM) patients before placement of levonorgestrel-releasing intrauterine system.Methods　A total of 150 type I AM patients with significantly enlarged uterus and unwilling to receive surgical treatment in Lianyungang Municipal Oriental Hospital Affiliated to Xuzhou Medical University from January 2017 to May 2019 were selected as the research objects.The patients were randomly divided into group A,group B and group C according to the digital table method,with 50 cases in each group.All patients began to take orally mifepristone on the first day to the third day of the menstrual cycle,once every night before going to bed.The doses of mifepristone in group A,group B,group C were 6.25,12.50 and 25.00 mg respectively.Levonorgestrel-releasing intrauterine system was placed until the depth of uterine cavity ≤ 8 cm.Before and 3 months after pretreatment,the depth of uterine cavity,uterine volume,endometrial thickness,menstrual volume and degree of dysmenorrhea of patients in the three groups were detected;the serum levels of estradiol,progesterone,follicle stimulating hormone and carbohydrate antigen 125 (CA125) of patients in the three groups were detected by enzyme-linked immunosorbent assay;the hemoglobin level of patients in the three groups was detected by blood cell analyzer.The time of drug pretreatment and adverse drug reactions were recorded;the incidence of adverse reactions related to levonorgestrel-releasing intrauterine system in 6 months after levonorgestrel-releasing intrauterine system was implanted.Results　There was no significant difference in depth of uterine cavity,uterine volume,endometrial thickness,pictorial blood loss assessment chart (PBAC) score and dysmenorrhea visual analogue scale (VAS) score of patients among the three groups before pretreatment(P>0.05).The depth of uterine cavity,uterine volume,endometrial thickness,PBAC score and VAS score of dysmenorrhea of patients after 3 months of pretreatment were lower than those before pretreatment in the three groups (P＜0.05).After 3 months of pretreatment,the depth of uterine cavity,uterine volume,endometrial thickness,PBAC score and dysmenorrhea VAS score of patients in group B and group C were lower than those in group A (P＜0.05);there was no significant difference in above indexes of patients between group B and group C (P>0.05).There was no significant difference in the levels of estradiol,progesterone,follicle stimulating hormone,CA125 and hemoglobin of patients among the three groups before pretreatment (P>0.05).After 3 months of pretreatment,the levels of estradiol,progesterone,follicle stimulating hormone and CA125 of patients were lower than those before pretreatment,and the level of hemoglobin was higher than that before pretreatment (P＜0.05).After 3 months of pretreatment,the levels of estradiol,progesterone,follicle stimulating hormone and CA125 of patients in group B and group C were lower than those in group A,and the level of hemoglobin of patients was higher than that in group A (P＜0.05);the levels of estradiol,progesterone,follicle stimulating hormone and CA125 of patients in group C were lower than those in group B,and the level of hemoglobin was higher than that in group B (P＜0.05).The pretreatment time of mifepristone in group A was longer than that in group B and group C (P＜0.05);there was no significant difference in pretreatment time of mifepristone between group B and group C (P>0.05).The incidence of adverse drug reactions in group A,group B and group C were 4.0%(2/50),18.0%(9/50) and 42.0%(21/50),respectively.The incidence of adverse drug reactions in group A was lower than that in group B（χ2=5.005，P＜0.05）；the incidence of adverse drug reactions in group B was lower than that in group C（χ2=6.857，P＜0.05）.The incidence of adverse reactions related to levonorgestrel-releasing intrauterine system in group A,group B and group C were 34.0%(17/50),12.0% (6/50) and 8.0%(4/50),respectively.The incidence of adverse reactions related to levonorgestrel-releasing intrauterine system in group B and group C was lower than that in group A（χ2=6.832，10.187；P＜0.05）；there was no significant difference in the incidence of adverse reactions related to levonorge-strel-releasing intrauterine system between group B and group C（χ2=0.444,P>0.05）.Conclusion　The daily dose of 12.5 mg of mifepristone for pretreatment before placement of levonorgestrel intrauterine sustained release system in type I AM patients has good clinical efficacy and less adverse reactions,which is worthy of clinical recommendation

参考文献/References:

［1］　涂皎,牟萌,古衡芳,等.左炔诺孕酮宫内缓释系统不同应用方法治疗子宫腺肌病疗效观察［J］.新乡医学院学报,2019,36(1):33-37.
［2］　SABBIONI L,PETRAGLIA F,LUISI S.Non-contraceptive benefits of intrauterine levonorgestrel administration:why not［J］.Gynecol Endocrinol,2017,33(11):822-829.
［3］　郎景和,冷金花,邓姗,等.左炔诺孕酮宫内缓释系统临床应用的中国专家共识［J］.中华妇产科杂志,2019,54(12):815-825.
［4］　张丽凤,杨慧,张信美,等.左炔诺孕酮宫内节育系统治疗子宫腺肌病患者的疗效和不良反应观察［J］.浙江大学学报(医学版),2019,48(2):130-135.
［5］　张信美.子宫腺肌病分型治疗的探讨［J］.妇产与遗传:电子版,2016,6(2):6-8.DOI:10.3868/j.issn.2095-1558.2016.02.003.
［6］　袁静,段华,孟戈,等.GnRH-a联合LNG-IUS在不同子宫体积时对子宫腺肌病疗效的影响分析［J］.中国实用妇科与产科杂志,2019,35(8):910-914.
［7］　郎景和,冷金花,王泽华,等.促性腺激素释放激素激动剂在子宫内膜异位症和子宫平滑肌瘤治疗中的应用专家意见［J］.中华妇产科杂志,2017,52(2):77-81.
［8］　徐肖文,朱雪琼,卢晓声,等.米非司酮用于左炔诺孕酮宫内缓释系统治疗子宫腺肌病前预治疗的临床对比研究［J］.医学研究杂志,2012,41(5):65-69.
［9］　谢幸,苟文丽,林仲秋,等.妇产科学［M］.8版.北京:人民卫生出版社,2013:273.
［10］　张信美.子宫腺肌病临床表现及其分型［J］.中国实用妇科与产科杂志,2019,35(5),498-501.
［11］　ZHANG P,SONG K,LI L,et al.Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis［J］.Med Princ Pract,2013,22(5) ：480.
［12］　MAGNAY J L,O′BRIEN S,GERLINGER C,et al．A systematic review of methods to measure menstrual blood loss［J］.BMC Women′s Health,2018,18(1):141-142.
［13］　HIGHAM J M,O′BRIEN P M,SHAW R W.Assessment of menstrual blood loss using a pictorial chart［J］.Br J Obstet Gynecol,1990,97(8)：734-739．
［14］　KIM M K,CHON S J,LEE J H,et al.Postoperative levonorgestrel-releasing intrauterine system insertion after gonadotropin-releasing hormone agonist treatment for preventing endometriotic cystrecurrence：a prospective observational study［J］.Reprod Sci,2018,25(1) ：39-43．
［15］　DEVI B K,陈正云,张信美.子宫腺肌病患者药物治疗进展［J］.浙江大学学报(医学版),2019,48(2):142-147.
［16］　韦佳佳,李晶晶,陈赛琼,等.依托孕烯植入剂与左炔诺孕酮宫内缓释系统的非避孕益处比较［J］.中国计划生育和妇产科,2019,11(10):71-75.
［17］　姜艳萍,张青冬,王楚平,等.左炔诺孕酮宫内缓释系统与小剂量米非司酮在子宫腺肌病治疗中的疗效比较研究［J］.中国全科医学,2017,20(S1):111-113.
［18］　杜洁贤,王康,田彩,等.不同预处理方式对曼月乐治疗弥漫性大子宫腺肌病效果的影响研究［J］.中国妇幼保健,2020,35(2):199-202.
［19］　刘跃,徐玲丽,朱伟华.经阴道彩色多普勒超声联合糖类抗原125在子宫腺肌症筛查中的应用价值［J］.中国药物与临床,2019,19(22):3858-3860.
［20］　王贤燕,刘颂.CA125和HE4在子宫腺肌症中的表达及临床检测价值研究［J］.中外女性健康研究,2017(20):70-71.
［21］　赵倩,秦玲,边爱平,等.诊断性刮宫、米非司酮口服防治 LNG-IUS治疗后不规则阴道出血效果观察［J］.山东医药,2013,53 (46):50-52.
［22］　陈钢,蒋秋丽.不同剂量米非司酮治疗子宫腺肌病的疗效比较研究［J］.安徽医药,2012,16(11):1677-1678.

相似文献/References:

[1]张科.不同药物治疗异位妊娠75例分析[J].新乡医学院学报,2000,17(02):138.
[2]晁宏图,陈忠萍.几种紧急避孕方法效果的比较[J].新乡医学院学报,2000,17(01):037.
[3]周玲生.子宫腺肌病178例临床病理分析[J].新乡医学院学报,2001,18(05):363.
[4]张淑爱.多疗程米非司酮治疗子宫肌瘤42例[J].新乡医学院学报,2003,20(05):380.
[5]．赵秀英,祝亚平,谢淑蓉.米非司酮加中药和氨甲喋呤治疗异位妊娠疗效比较[J].新乡医学院学报,2003,20(05):342.
[6]赵秀英,祝亚平,谢淑蓉.米非司酮加中药和氨甲喋呤治疗异位妊娠疗效比较[J].新乡医学院学报,2003,20(05):342.
[7]张淑爱.多疗程米非司酮治疗子宫肌瘤42 例[J].新乡医学院学报,2003,20(05):380.
[8]叶琳,王秀叶.米非司酮和米索前列醇配合清宫术治疗稽留流产的临床观察[J].新乡医学院学报,2008,25(02):156.
[9]南　燕,侯妍妍,李玉洁.不同剂量米非司酮对子宫内膜异位症大鼠异位内膜组织中环氧合酶-2和血管内皮生长因子表达的影响[J].新乡医学院学报,2019,36(6):521.[doi:10.7683/xxyxyxb.2019.06.005]
　NAN Yan,HOU Yan-yan,LI Yu-jie.Effect of different doses of mifepristone on the expression of cyclooxygenase-2 and vascular endothelial growth factor in endometriosis rats[J].Journal of Xinxiang Medical University,2019,36(12):521.[doi:10.7683/xxyxyxb.2019.06.005]
[10]涂　皎,牟　萌,古衡芳,等.左炔诺孕酮宫内缓释系统不同应用方法治疗子宫腺肌病疗效观察[J].新乡医学院学报,2019,36(1):033.[doi:10.7683/xxyxyxb.2019.01.007]
　TU Jiao,MOU Meng,GU Heng-fang,et al.Effect of different application methods of levonorgestrel intrauterine sustained-release system in the treatment of adenomyosis[J].Journal of Xinxiang Medical University,2019,36(12):033.[doi:10.7683/xxyxyxb.2019.01.007]

更新日期/Last Update: 2021-12-05